Navigation Links
Amgen's Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51
Date:1/23/2013

THOUSAND OAKS, Calif., Jan. 23, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2012. Key results include:

  • For the full year, total revenues increased 11 percent to $17,265 million, with 9 percent product sales growth driven by strong performance across the portfolio. Adjusted EPS grew 22 percent to $6.51 due to 15 percent adjusted operating income growth and lower shares outstanding. 
  • For the fourth quarter, total revenues increased 11 percent to $4,421 million, with product sales growing at the same rate. Adjusted EPS grew 16 percent to $1.40 due to 11 percent adjusted operating income growth and lower shares outstanding. 
  • GAAP EPS were $1.01 in the fourth quarter compared to $1.08 a year ago, and were $5.52 for the full year compared to $4.04 in 2011. Full year 2011 was negatively impacted by a previously disclosed charge for a legal settlement reserve.
  • Free cash flow for the full year was $5.2 billion compared to $4.5 billion in 2011.
  • The Company announced that it has initiated Phase 3 studies for AMG 145 in subjects with high levels of low-density lipoprotein (LDL) cholesterol. 
  • "We achieved strong operating performance in 2012 as we delivered for patients and created value for shareholders," said Robert A. Bradway, chairman and chief executive officer at Amgen.  "We enter 2013 with good momentum, a broad late-stage pipeline and a continued focus on building our business internationally."Year-over-YearYear-over-Year$Millions, except EPS and percentagesQ4 '12Q4 '11YOY ΔFY '12FY '11YOY ΔTotal Revenues$4,421$3,97311%$17,265$15,58211%Adjusted Net Income1,0881,0395%5,1194,8585%Adjusted EPS1.401.2116%6.515.3322%GAAP Net Income788934(16%)4,3453,68318%GAAP EPS$1.01$1.08(6%)$5.52$4.0437%References in this release to
    '/>"/>

    SOURCE Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
    2. MDHI Receives Term Sheet for Working Capital and Acquisition Financing -- Company Hits Profitability on Recurring Revenues
    3. Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board
    4. InfuSystem Holdings, Inc. Reports $14.1 Million of Revenues for the Second Quarter of 2012; Announces Annualized Cost Savings in Excess of $1 million
    5. AMILPAR - Revenues Grow 18% and EBITDA Increases 19% in 1H12
    6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
    7. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
    8. CitiusTech Announces H1 2012 Results - 65% Growth in Half Year Revenues
    9. Herborium Group Reports Record 6 Month Revenues
    10. InfuSystem Holdings, Inc. Reports $14.3 Million of Revenues And $1.6 Million Of EBITDA For The First Quarter Of 2012
    11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... , Aug. 20, 2014 The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kansas blocked the sale of ...
    (Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Impact of ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... 3590) is complex legislation that affects virtually every ... provisions are beginning to take effect now. IVD ...
    (Date:8/20/2014)... 20, 2014 Research and Markets ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and ... report to their offering. A ... and geography) - Size, Share, Global Trends, Company ... and Forecast, 2013 - 2020", suggests that the ...
    Breaking Medicine Technology:Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2
    ... 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 2012.  For the first quarter of 2012, the Company reported ... compared with a net income of $2.9 million, or $0.05 ... $3.8 million change in operating results is primarily due to ...
    ... Janssen Research & Development, LLC, (Janssen), announced today ... to the U.S. Food and Drug Administration (FDA) seeking ... an oral anticoagulant, to treat patients with deep vein ... recurrent venous thromboembolism (VTE). These submissions are ...
    Cached Medicine Technology:Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8
    (Date:8/20/2014)... Today, Zane Benefits, the #1 ... a new eBook, Affordable Care Act 101. , ... feel uncertain about how the ACA impacts their ... line. , The new eBook outlines key ACA ... their upcoming health insurance decisions. , Read the ...
    (Date:8/20/2014)... Locating rates for insurance packages will now be an ... new source of term life insurance providers has been added ... 50 states at http://quotespros.com/life-insurance.html . , The database ... available for the public to find out the exact annual ... quotations that are available are good through the rest of ...
    (Date:8/20/2014)... group representing U.S. obstetricians is calling for all pregnant ... the American College of Obstetricians and Gynecologists (ACOG), several ... and effectiveness of flu vaccination during pregnancy. "The ... dangerous to pregnant women, as it can cause pneumonia, ... of the college,s Immunization Expert Work Group, explained in ...
    (Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, ... a group of rhesus monkeys from deadly Marburg virus, a ... 90 percent of those it infects, researchers report. The ... virus, even when it was given three days after infection, ... Science Translational Medicine . This is the first ...
    (Date:8/20/2014)... Line: Less than 42 percent of women underwent ... the factors associated with foregoing reconstruction included being ... older. , Author: Monica Morrow, M.D., of the ... colleagues. , Background: The Women,s Health and Cancer ... breast reconstruction following a mastectomy. Still, most women ...
    Breaking Medicine News(10 mins):Health News:Term Life Insurance Price Database Now Helps Quote Prices for Adults in 50 States Online 2Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 3Health News:Patient perspectives on breast reconstruction following mastectomy 2
    ... By Tobacco Advertising and Find It,Easy to Buy Cigarettes, ... against tobacco on April 2 as they join thousands ... Day, sponsored by the Campaign,for Tobacco-Free Kids. Hundreds of ... local events, go to http://www.kickbuttsday.org/events )., This ...
    ... March 27 The Richard B. and,Lynne V. ... John Ray have joined the Institute,s Board of ... for the Institute., "Mary Matalin,s experience in ... to the Institute as we build our organization ...
    ... Calif., March 27 Clarient, Inc.,(Nasdaq: CLRT ), ... the pharmaceutical industry, today announced,that it is scheduled to ... Co.,9th Annual Las Vegas Investor Conference at 4:00 p.m. ... conference is being held at the Palms,Casino Resort April ...
    ... Now Have Choices and Flexibility ... Typically Available on Larger Plans, NEW YORK, ... to,nine employees can now choose from a wider selection of ... larger,companies., The Guardian Life Insurance Company of America (Guardian), ...
    ... a mental rigidity that keeps them from folding their ... form of mental rigidity that leads to compulsive behavior ... luck even when they,re on a losing streak, a ... causes compulsive gambling, but it,s been suggested that environmental ...
    ... CHICAGO, IL MARCH 27, 2008 The Cardiovascular ... meta-analysis to date comparing mortality rates for drug-eluting stents ... Stent Revolution VII meeting tomorrow evening in Chicago. ... studieswas performed by a team of researchers led by ...
    Cached Medicine News:Health News:D.C. Kids 'Kick Butts' on April 2 2Health News:D.C. Kids 'Kick Butts' on April 2 3Health News:Mary Matalin and John Ray Join the Cheney Cardiovascular Institute Board of Directors 2Health News:Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference 2Health News:Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost 2Health News:Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost 3Health News:Compulsive Gamblers Don't Learn From Their Mistakes 2Health News:Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use 2
    Bone Curette, 170 mm...
    Bone Currettes...
    Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
    ...
    Medicine Products: